News
-
-
PRESS RELEASE
Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
Heidelberg Pharma appoints Dr. Dongzhou Jeffery Liu as Chairman and CEO, replacing Prof. Andreas Pahl. The biotech company focuses on ADC technology for cancer treatment -
-
PRESS RELEASE
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
Heidelberg Pharma AG announces changes to the Executive Management Board - Dr. Dongzhou Jeffery Liu appointed as Chairman of the Executive Board and Chief Executive Officer -
-
PRESS RELEASE
Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Heidelberg Pharma's lead ATAC candidate HDP-101 shows promising progress in Phase I/IIa trial for multiple myeloma, including stringent complete remissions. R&D webinar scheduled on 11 Nov 2025 -
-
PRESS RELEASE
Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
Heidelberg Pharma to present new clinical data of lead ADC candidate HDP-101 at the World ADC Congress 2025 and host a webinar. Study results show promising anti-tumor activity in multiple myeloma patients -
-
PRESS RELEASE
Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Heidelberg Pharma's lead ADC candidate HDP-101 granted Fast Track Designation by US FDA for the treatment of multiple myeloma. Accelerated review for innovative cancer therapy
